Galmed Pharmaceuticals Becomes EoCene, Unveiling New Ticker Symbol “EOCN” to Reflect its New Dawn Platform for GI Innovation
September 9, 2026
Qualigen Therapeutics’ Pan-RAS Inhibitor Featured in Two Abstracts at American Society for Clinical Oncology (ASCO) 2022 Annual Meeting
May 26, 2022
Related Post
-
-
Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis
September 4, 2026
-
Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program
September 3, 2026
-
NorthStrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination for Potential Cardiac Disease and Obesity Therapeutic Applications
September 1, 2026